It’s not surprising that the diabetes space is fertile ground for innovation. The Journal of the American Medical Association just announced that 50% of adults in the US have diabetes or pre-diabetes. And, when it comes to monitoring diabetes, it’s still a painful (literally) experience. Most people still perform the daily chore of manually drawing blood samples by pricking a finger with a lancing device and using test strips to measure the results.
This week, Sanofi and Alphabet Life Sciences (Google) announced a partnership to develop new ways to monitor and treat diabetes. This marks the third major alliance for Alphabet (Google) with pharmaceutical brands and device makers in the field of diabetes monitoring.
First came the 2014 Novartis (Alcon)/Google partnership for a glucose-sensing contact lens, which was followed by the more recent Dexcom/Google partnership for a bandage-thin continuous glucose monitor.
And, now, Sanofi/Alphabet Life Sciences is working on “small, connected medical devices to continuously collect diabetes-related data, as well as software that learns from the information to find new treatments.” While it’s not entirely clear how these devices will work or how they will collect data, they are reported to be focused on “health ‘indicators,’ which include measuring blood-glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.”
As pharmaceutical brands continue to work to improve patient (and physician) experience, partnerships that take technologies from R&D to market are exciting to watch. They have the potential to truly change the way we manage our health.
For more on our Innovation from Insiders Trend, check out Health Trends #1.